Factor VIII Inhibitors in Patients with Hemophilia A

Publisher： Karger

E-ISSN： 1421-9662|102|1|42-46

ISSN： 0001-5792

Source： Acta Haematologica, Vol.102, Iss.1, 1999-09, pp. : 42-46

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Treatment of Factor VIII Inhibitors with Selective IgG Immunoadsorption – a Single Center Experience in 50 Patients with Acquired Hemophilia*

By  

Transfusion Medicine and Hemotherapy, Vol. 33, Iss. 2, 2006-03 ,pp. : 160-164

Karger

Access to resources Recommend Favorite

Half‐life extended factor VIII for the treatment of hemophilia A

By  

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Vol. 13, Iss. S1, 2015-06 ,pp. : S176-S179

John Wiley & Sons Inc

Access to resources Recommend Favorite

The pharmacokinetics of a B‐domain truncated recombinant factor VIII, turoctocog alfa (NovoEight®), in patients with hemophilia A

By  

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Vol. 13, Iss. 3, 2015-03 ,pp. : 370-379

John Wiley & Sons Inc

Access to resources Recommend Favorite

Pharmacoeconomic analysis of recombinant factor VIIa versus APCC in the treatment of minor-to-moderate bleeds in hemophilia patients with inhibitors

By Joshi Ashish V.   Stephens Jennifer M.   Munro Vicki   Mathew Prasad   Botteman Marc F.  

Current Medical Research and Opinion, Vol. 22, Iss. 1, 2006-01 ,pp. : 23-31

Informa Healthcare

Access to resources Recommend Favorite

Activated Recombinant Human Coagulation Factor VII Therapy for Intracranial Hemorrhage in Patients with Hemophilia A or B with Inhibitors

By  

Pathophysiology of Haemostasis and Thrombosis, Vol. 28, Iss. 2, 1999-03 ,pp. : 93-98

Karger

Access to resources Recommend Favorite